Clinical trial
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response…
NCT00110006 · Case Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00110006 |
|---|---|
| Title | Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma |
| Official title | Prognostic Significance of Early Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F] FDG) in Intermediate and High Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography, fludeoxyglucose F 18 |
| Enrollment | 0 |
| Start date | Dec 1, 2004 |
| First posted | May 4, 2005 |
| Last update posted | Jun 11, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: